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by alternative complement pathway dysregulation, leading
to systemic thrombotic microangiopathy (TMA) and
severe end-organ damage. Based on 2 prospective studies
in mostly adults and retrospective data in children,
eculizumab, a terminal complement inhibitor, is approved
for aHUS treatment. Here we prospectively evaluated
efﬁcacy and safety of weight-based dosing of eculizumab
in eligible pediatric patients with aHUS in an open-label
phase II study. The primary end point was complete TMA
response by 26 weeks. Twenty-two patients (aged 5
months–17 years) were treated; 16 were newly diagnosed,
12 had no prior plasma exchange/infusion during current
TMA symptomatology, 11 received baseline dialysis, and
2 had prior renal transplants. By week 26, 14 achieved
a complete TMA response, 18 achieved hematologic
normalization, and 16 had 25% or better improvement
in serum creatinine. Plasma exchange/infusion was
discontinued in all, and 9 of the 11 patients who required
dialysis at baseline discontinued, whereas none initiated
new dialysis. Eculizumab was well tolerated; no deaths or
meningococcal infections occurred. Bone marrow failure,
wrist fracture, and acute respiratory failure were reported
as unrelated severe adverse events. Thus, our ﬁndings
establish the efﬁcacy and safety of eculizumab for pediatric
patients with aHUS and are consistent with proposed
immediate eculizumab initiation following diagnosis in
children.
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A typical hemolytic uremic syndrome (aHUS) is a pro-gressive life-threatening thrombotic microangiopathy(TMA) associated with dysregulation of the comple-
ment alternative pathway.1–3 Complement gene mutations
(e.g., complement factor H [CFH], membrane cofactor pro-
tein [MCP], complement factor I [CFI], complement factor
B [CFB], complement protein 3 [C3]), or factor H autoanti-
bodies are identiﬁed in 50% to 60% of patients with aHUS.4–6
Abnormalities in genes encoding thrombomodulin, plasmin-
ogen, and diacylglycerol kinase ε (DGKE)7–9 occur in a small
number of patients. Evidence of a genetic abnormality is not
required for diagnosis.4,10–13
Although onset may occur at any age, 40% of patients
develop aHUS by 18 years of age.1,2,5 Clinical manifestations
in children generally include anemia, thrombocytopenia,
and acute kidney injury,5 but peripheral gangrene,14 arterial
stenoses,15 dilated cardiomyopathy, cardiorespiratory arrest,16
and neurologic,5,17 pulmonary,11 and gastrointestinal
complications17 have been reported. Historically, aHUS was
managed with plasma exchange/plasma infusion (PE/PI) and
was associated with high morbidity and mortality rates,1–3,5,18
with children having higher mortality than adults.5 PE/PI
may induce stabilization of hematologic parameters (but
generally not signiﬁcant renal function improvement),19 is
associated with complications, and impairs quality of life.19,20
The availability of eculizumab (Soliris, Alexion Pharma-
ceuticals, Inc., Cheshire, CT, USA)21,22— an anti-C5 mono-
clonal antibody and the ﬁrst and only currently approved
therapy for adult and pediatric patients—has profoundly
changed aHUS management.13,23 The efﬁcacy and safety of701
Table 1 | Baseline demographics and disease characteristics
Variable
Intent-to-treat
population
(N [ 22)
Median age at ﬁrst infusion, yr (range) 6.5 (0.4–17)
Age range, n (%)
1 mo to <23 mo (n ¼ 5) 5 (23)
$23 mo to <5 yr (n ¼ 5) 5 (23)
c l i n i ca l t r i a l LA Greenbaum et al.: Eculizumab in pediatric patients with aHUSeculizumab was demonstrated in 2 prospective clinical trials
of primarily adult patients with progressing TMA, long dis-
ease duration, and chronic kidney disease.24,25 Use in children
with aHUS is supported by case reports13,16,26–37 and a
retrospective study.38,39 To further establish the efﬁcacy and
safety of eculizumab, a prospective clinical trial in patients
with aHUS aged <18 years was conducted. Primary analysis
results after 26 weeks of treatment are presented here.$5 to <12 yr (n ¼ 8) 8 (36)
$12 to <18 yr (n ¼ 4) 4 (18)
Median weight, kg (range) 20 (7–95)
Female sex, n (%) 10 (45)
Race, n (%)
Asian 2 (9)
Black or African American 0
White 18 (82)
Other 2 (9)
Patient-reported family history of aHUS, n (%) 6 (27)
Identiﬁed complement gene mutation, autoantibody,
or polymorphism, n (%)
11 (50)
MCPa 3 (14)
CFHb 2 (9)
CFIc 2 (9)
CFH autoantibody 2 (9)
CFHR1/3 deletion (homozygous) 1 (5)
C3d 1 (5)
eRESULTS
Patients and treatment
Twenty-two patients were treated with eculizumab, and 19
(86%) completed the 26-week treatment period (Figure 1).
Three patients discontinued treatment before week 26. Pa-
tients were exposed to eculizumab for a mean of 5.5 months
(SD, 1.3 months).
Patients ranged in age from 5 months to 17 years (median
age, 6.5 years) (Table 1). Median weight was 20 kg (range,
795 kg). Eleven (50%) had $1 identiﬁed complement gene
abnormality or factor H autoantibody. One patient (5%) had
a DGKE mutation. Six patients (27%; all <12 years of age)
had a family history of aHUS. Sixteen patients (73%) wereFigure 1 | Patient disposition. aLDH $ 1.5  ULN; hemoglobin
# LLN; fragmented red blood cells with a negative Coombs test
result. bOne patient had a positive test for STEC infection, 1 had a
normalized platelet count; 2 had a ﬁnal diagnosis that was not aHUS,
1 had unspeciﬁed reasons. aHUS, atypical hemolytic uremic
syndrome; LDH, lactate dehydrogenase; LLN, lower limit of normal;
SAE, serious adverse event; SCr, serum creatinine; STEC, Shiga-like
toxin-producing Escherichia coli; ULN, upper limit of normal.
Identiﬁed DGKE mutation, n (%) 1 (5)
Median duration from aHUS diagnosis until screening,
mo (range)
0.6 (0–191)
Median duration of current manifestation to ﬁrst
dose, mo (range)
0.2 (0–4)
Newly diagnosed patients, n (%) 16 (73)
No PE/PI during current manifestation, n (%) 12 (55)
Dialysis at baseline, n (%)f 11 (50)
Previous renal transplant, n (%) 2 (9)
Mean platelet count, 109/l (SD) 88 (42)
Platelet count <150 109/l, n (%) 22 (100)
Mean LDH level, U/l (SD) 1944 (1824)
LDH greater than ULN, n (%) 19 (86)
Mean hemoglobin concentration, g/dl (SD) 8.0 (1.5)
Mean serum creatinine level, mg/dl (SD) 1.7 (1.3)
Mean eGFR, ml/min per 1.73 m2 (SD) 33 (30)
eGFR (ml/min per 1.73 m2), n (%)
<15 10 (46)
15–29 4 (18)
30–44 2 (9)
45–59 2 (9)
60–89 2 (9)
$90 2 (9)
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H; CFHR,
CFH-related protein; CFI, complement factor I; DGKE, diacylglycerol kinase ε; eGFR,
estimated glomerular ﬁltration rate; LDH, lactate dehydrogenase; MCP, membrane
cofactor protein; PE/PI, plasma exchange/infusion; ULN, upper limit of normal.
aMCP mutations: IVS3-2; p.Arg59Stop (c.175 C > T); p.Tyr189Asp (c.565 T > G).
bCFH mutations: p.Ser1191Leu and p.Val1197Ala; p.Ser1191Leu.
cCFI mutations: p.Ile340Thr (1019T > C) and p.Gly424Asp (1271G > A); p.Gly269Ser.
dC3 mutation: p.Arg102Glyc (c.304C > G).
eAfter completion of the trial, patients with aHUS onset at <1 year of age and ev-
idence of proteinuria (n ¼ 3) were screened for DGKE mutations.
fIncludes 1 patient who was receiving dialysis at baseline and discontinued dialysis
during the baseline window before the ﬁrst dose of eculizumab.
702newly diagnosed. Ten patients (45%) received PE/PI at
baseline. Overall, 18 patients (82%) had a baseline estimated
glomerular ﬁltration rate (eGFR) <60 mL/min per 1.73 m2,
including 10 patients (64%) who had an eGFR <15 mL/minKidney International (2016) 89, 701–711
LA Greenbaum et al.: Eculizumab in pediatric patients with aHUS c l i n i ca l t r i a lper 1.73 m2. Eleven patients (50%) were receiving dialysis at
baseline for a total median pretreatment duration of 13 days
(range, 14826 days) and for 7 days (range, 136 days)
during the current TMA manifestation (n ¼ 10). Two patients
(9%) had a history of renal transplantation for end-stage renal
disease from aHUS.
Efﬁcacy
Primary end point. Efﬁcacy end points calculated for the
intent-to-treat population are summarized in Table 2. By
week 26, 14 patients (64%) achieved the primary end point of
complete TMA response after a median of 8.6 weeks (range,
1–21.9 weeks).
TMA outcomes. TMA event-free status was achieved in 21
patients (95%) (Table 2). Between baseline and 26 weeks, the
median TMA intervention rate was reduced from 0.4 to
0 events per patient per day, respectively (P < 0.0001). By
study day 31, PE/PI was discontinued in all 10 patients who
required it at baseline.
Hematologic outcomes. Hematologic normalization was
achieved in 18 patients (82%) after a median of 55 days
(range, 1–153 days). Twenty-one patients (95%) achieved
platelet count normalization after a median of 7 days (range,
1–80 days) (Table 2). The 1 patient who did not achieve
platelet count normalization withdrew after a single dose of
eculizumab because of a diagnosis of Shiga-like toxin-pro-
ducing Escherichia coli hemolytic uremic syndrome (Figure 1).Table 2 | Summary of efﬁcacy results after 26 weeks of
eculizumab therapy
Study end point
Total
(N [ 22)
Primary end point
Complete TMA response
n (%) 14 (64)
95% CI 41–83
TMA outcome
TMA event-free status
n (%) 21 (95)
95% CI 77–100
Hematologic outcomes
Hematologic normalization
n (%) 18 (82)
95% CI 60–95
Platelet count normalization
n (%) 21 (95)
95% CI 77–99
LDH normalization
n (%) 18 (82)
95% CI 60–95
Hemoglobin improvement $2 g/dl
n (%) 15 (68)
95% CI 45–86
Renal outcomes
Serum creatinine level decrease by $25%, n (%) 16 (73)
eGFR improvement by $15 ml/min per 1.73 m2, n (%) 19 (86)
CKD improvement by $1 stage, n (%) 17 (77)
CI, conﬁdence interval; CKD, chronic kidney disease; eGFR, estimated glomerular
ﬁltration rate; LDH, lactate dehydrogenase; TMA, thrombotic microangiopathy.
Kidney International (2016) 89, 701–711Eculizumab was associated with a rapid and sustained
increase in platelet count from baseline to 27 weeks
(P # 0.0001) (Figures 2 and 3). The mean improvement in
platelet count at 27 weeks was 164  109/L (SD, 76  109/L).
Lactate dehydrogenase (LDH) normalization was achieved in
18 patients (82%) after a median of 48 days (range, 1–153
days). Fifteen patients (68%) had an improvement in hemo-
globin of $2 g/dL.
Renal outcomes. A decrease in serum creatinine level
by $25% occurred in 16 patients (73%) (Table 2) after a
median of 21 days (range, 2–140 days). Nineteen (86%)
patients had eGFR improvement of $15 ml/min per 1.73 m2.
The mean improvement from baseline to week 27 in eGFR
was 64 ml/min per 1.73 m2 (P < 0.0001) (Figures 4 and 5).
Among 20 patients with chronic kidney disease (CKD) stage
>2, 17 (85%) had improvement of $1 stage. Nine of
11 patients (82%) receiving dialysis at baseline discontinued
dialysis during the study after a median of 7 days (range,
415 days; n ¼ 8); of these, 1 discontinued dialysis before
eculizumab initiation. All 11 patients not receiving baseline
dialysis remained dialysis free. Two patients (9%) were
receiving dialysis at week 26.
Efﬁcacy by mutational status. The efﬁcacy of eculizumab
was observed in patients with (n ¼ 11) and those without
(n ¼ 11) identiﬁed complement abnormalities (complement
gene mutations or polymorphisms or factor H autoanti-
bodies, or both). Complete TMA response was achieved in
8 patients (73%) with and 6 patients (55%) without abnor-
malities. TMA event-free status was achieved by 11 patients
(100%) and 10 patients (91%) with and without abnormal-
ities, respectively. Ten patients (90%) with and 8 patients
(73%) without complement abnormalities met criteria for
hematologic normalization. eGFR improvement $15 ml/min
per 1.73 m2 occurred in 11 patients (100%) and 8 patients
(73%) with and without abnormalities, respectively.
The patient with the identiﬁed DGKE mutation dis-
continued dialysis at initiation of eculizumab treatment and
did not require dialysis during the study. This patient ach-
ieved complete TMA response, TMA event-free status, and
hematologic normalization by week 26.
Post hoc analysis of patient characteristics by criteria for the
primary end point. Table 3 shows the baseline demographic
characteristics of patients who did (n ¼ 14) and those who
did not (n ¼ 8) meet criteria for the primary end point at
26 weeks. The subgroup of patients who did not achieve
complete TMA response had a lower frequency of identiﬁed
complement abnormalities (38% compared with 57%) as well
as worse renal function at baseline. Sixty-three percent of
patients with baseline eGFR <15 ml/min per 1.73 m2 did not
achieve complete TMA response.
Patients who did and those who did not achieve complete
TMA response had a similar duration of exposure to eculi-
zumab (mean, 5.7 months [SD, 0.7 months] and 5.0 months
[SD, 2.0 months], respectively). These subgroups received a
mean of 14.3 eculizumab infusions (SD, 2.2) and 11.5 eculi-
zumab infusions (SD, 4.9), respectively.703
Figure 2 | Improvement in platelet count over 27 weeks of eculizumab treatment. N values <5 were not included. Bars represent SEM.
Arrows denote administration of eculizumab.
c l i n i ca l t r i a l LA Greenbaum et al.: Eculizumab in pediatric patients with aHUSHealth-related quality of life
The pediatric Functional Assessment of Chronic Illness
Therapy—Fatigue least squares mean change from baseline to
week 27 was 19.7 (range, 15.6–23.7; P < 0.0001; n ¼ 5).
Pharmacokinetics and pharmacodynamics
Clearance and volume of distribution of the central
compartment values were 0.0104 l/h and 5.23 l, respectively;Figure 3 | Improvement in platelet count over 27 weeks of eculizum
704between-subject variability was low and consistent with
previous studies.24 The elimination half-life of eculizumab
was 14.5 days. Overall, individual minimum concentration
(Cmin) values were generally >50 mg/ml, and maximum
concentration (Cmax) values were <700 mg/ml in each
age cohort (Table 4). Mean area under the concentration
time curve (AUC) values decreased with increasing age
during induction. After 24 hours, all 18 patientsab treatment in individual patients.
Kidney International (2016) 89, 701–711
Figure 4 | Improvement in estimated glomerular ﬁltration rate (eGFR) over 27 weeks of eculizumab treatment. N values <5 were not
included. Bars represent SEM. Arrows denote administration of eculizumab.
LA Greenbaum et al.: Eculizumab in pediatric patients with aHUS c l i n i ca l t r i a lwith evaluable data had evidence of complete terminal
complement inhibition. One patient (30 months old), who
tested positive for human antihuman antibodies (HAHAs),
had a Cmin <50 mg/ml on study days 36 and 91. On day 121,
the patient had conﬁrmed evidence of HAHAs, an eculizu-
mab trough concentration of 17.1 mg/ml, and decreased
inhibition of hemolytic activity. The patient did not haveFigure 5 | Improvement in estimated glomerular ﬁltration rate (eGF
Kidney International (2016) 89, 701–711pharmacokinetic (PK) samples out of the target range or
incomplete inhibition of hemolysis at any other time point
during the maintenance phase. The patient did not achieve
complete TMA response, achieved hematologic normaliza-
tion after the ﬁrst eculizumab dose, did not have improve-
ment in eGFR or serum creatinine level, and was receiving
dialysis at baseline and 26 weeks.R) over 27 weeks of eculizumab treatment in individual patients.
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Table 3 | Baseline demographics and disease characteristics
of patients who did and those who did not meet criteria for
the primary end point (post hoc analysis)
Variable
Achieved
complete TMA
response
(n [ 14)
Did not achieve
complete TMA
response
(n [ 8)
Median age at ﬁrst infusion, yr
(range)
7.5 (0.0–17.0) 2.0 (0.0–17.0)
Age range, n (%)
1 mo to <23 mo (n ¼ 5) 3 (21) 2 (25)
$23 mo to <5 yr (n ¼ 5) 2 (14) 3 (38)
$5 to <12 yr (n ¼ 8) 6 (43) 2 (25)
$12 to <18 yr (n ¼ 4) 3 (21) 1 (13)
Median weight, kg (range) 22 (7–68) 14 (8–95)
Female sex, n (%) 7 (50) 3 (38)
Race, n (%)
Asian 1 (7) 1 (13)
Black or African American 0 (0) 0 (0)
White 11 (79) 7 (88)
Other 2 (14) 0 (0)
Patient-reported family history
of aHUS, n (%)
3 (21) 3 (38)
Identiﬁed complement gene mutation,
autoantibody,
or polymorphism, n (%)
8 (57) 3 (38)
MCP 3 (21) 0 (0)
CFH 1 (7) 1 (13)
CFI 1 (7) 1 (13)
CFH autoantibody 2 (14) 0 (0)
CFHR1/3 deletion (homozygous) 1 (7) 0 (0)
C3 0 (0) 1 (13)
No identiﬁed complement gene
mutation, autoantibody, or
polymorphism, n (%)
6 (43) 5 (63)
Median duration from aHUS diagnosis
until screening, mo (range)
0 (0–191) 0 (0–58)
Median duration of current
manifestation to ﬁrst dose,
mo (range)
0.2 (0–4) 0.2 (0–1)
Newly diagnosed patients, n (%) 10 (71) 6 (75)
No PE/PI during current manifestation,
n (%)
NA NA
Dialysis at baseline, n (%) 6 (43) 5 (63)
Previous renal transplant, n (%) 2 (14) 0 (0)
Mean platelet count, 109/l (SD) 85 (44) 91 (41)
Platelet count <150 109/l, n (%) 14 (100) 8 (100)
Mean LDH level, U/l (SD) 1923 (1670) 1979 (2192)
LDH greater than the ULN, n (%) 14 (100) 5 (63)
Mean hemoglobin concentration,
g/dl (SD)
8 (1.3) 8 (2.0)
Mean serum creatinine level, mg/dl
(SD)
2.0 (1.5) 1.2 (0.8)
Mean eGFR, ml/min per 1.73 m2 (SD) NA NA
eGFR (ml/min per 1.73 m2), n (%)
<15 5 (36) 5 (63)
15–29 2 (14) 2 (25)
30–44 2 (14) 0 (0)
45–59 2 (14) 0 (0)
60–89 2 (14) 0 (0)
$90 1 (7) 1 (13)
aHUS, atypical hemolytic uremic syndrome; CFH, complement factor H;
CFHR, CHF-related protein; CFI, complement factor I; eGFR, estimated glomer-
ular ﬁltration rate; LDH, lactate dehydrogenase; MCP, membrane cofactor pro-
tein; PE/PI, plasma exchange/infusion; ULN, upper limit of normal.
c l i n i ca l t r i a l LA Greenbaum et al.: Eculizumab in pediatric patients with aHUS
706Safety
Treatment-emergent adverse events (TEAEs) occurred in
20 patients (Table 5); most were mild or moderate in
severity, and the most common were fever, cough, abdominal
pain, diarrhea, and upper respiratory tract infection. Of these
events, 3 (occurring in 2 patients who were 1 month to
<23 months of age and in 1 patient who was 5 to <12 years
of age) were judged to be severe: bone marrow failure, wrist
fracture, and acute respiratory failure. Bone marrow failure
was diagnosed after laboratory results showed anemia,
thrombocytopenia, mild hemolysis, and low white blood cell
count; the severity of the anemia and associated neutropenia
and thrombocytopenia were attributed to both aHUS and
effects of a viral infection. The investigator reported the bone
marrow failure as viral-induced bone marrow suppression;
the patient had a parainﬂuenza type 3 infection during the
same period. A bone marrow biopsy was not performed. The
patient was treated with packed red blood cells and recov-
ered. The event of acute respiratory failure occurred in a
patient with choking and vomiting followed by a sudden
onset of respiratory distress that required intubation. Both
patients recovered and remained on study medication;
neither severe TEAE was judged to be related to eculizumab.
Thirteen patients (59%) reported $1 serious TEAE
(Table 5), 1 of which (agitation of moderate severity) led to
treatment discontinuation. The patient with HAHAs
remained on eculizumab without safety concerns. No deaths
or meningococcal infections occurred.
Elevated levels of alanine transaminase and aspartate
aminotransferase were noted in some patients before and
after receiving eculizumab. More patients had elevated levels
before baseline and at day 0 compared with after baseline, and
most patients had enzyme level normalization by week 26.
This trend was consistently observed for patients with
elevations >3 times the upper limit of normal (ULN).
The patient who discontinued the study because of the
serious TEAE of agitation had no identiﬁed complement
abnormality and did not have TMA complications after 1 year
of follow-up. One additional patient who withdrew from the
study because of a family request was not followed after
consent was withdrawn.
DISCUSSION
We are reporting the ﬁrst prospective trial conducted
exclusively in patients with aHUS <18 years of age. Eculi-
zumab treatment led to complete TMA response in 64% of
patients after 26 weeks, and the majority met criteria for
improvements in all hematologic and renal parameters.
Clinical beneﬁts were demonstrated by the discontinuation
of PE/PI in all patients and discontinuation of dialysis in
82% of patients who required it at baseline. Patients who
did not require baseline dialysis did not progress to end-
stage renal disease or require dialysis during treatment.Kidney International (2016) 89, 701–711
Table 4 | Eculizumab descriptive statistics of AUC, Cmax, and Cmin values by age group
Population Parametera
Induction period Maintenance period
Mean (CV%) Median (range) Mean (CV%) Median (range)
$1 to <23 mo
(n ¼ 5)
AUC (mg/hr/ml) 58,600.6 (35.3) 50,908.0 (40,748.5L88,516.6) 147,276.8 (18.1) 152,045.0 (104,500.5L177,946.5)
Cmax (mg/ml) 421.5 (40.1) 372.0 (282.4L686.2) 519.1 (8.0) 513.7 (467.6L583.5)
Cmin (mg/ml) 287.2 (31.0) 244.4 (207.8L396.2) 215.0 (36.1) 185.6 (146.0L342.7)
$23 mo to <5 yr
(n ¼ 5)
AUC (mg/hr/ml) 52,814.9 (14.9) 49,476.6 (44,561.5L64,680.8) 106,864.6 (36.5) 115,749.7 (43,652.9L139,521.9)
Cmax (mg/ml) 377 (17.1) 386.2 (290.3L439) 424.0 (24.2) 449.7 (267.4L534.3)
Cmin (mg/ml) 262.8 (21.2) 252.4 (188.9L337.5) 235.9 (48.3) 257.1 (50.2L338)
$5 to <12 yr
(n ¼ 8)
AUC (mg/hr/ml) 35,380.9 (11.7) 35,354.7 (29,667.2–39,716.4) 160,471 (28.1) 151,654.5 (117,194.4L261,814.4)
Cmax (mg/ml) 244 (11.3) 240.2 (205.0L282.2) 636.1 (30.6) 580.9 (461.0L1094.4)
Cmin (mg/ml) 181.4 (12.6) 184.2 (143.8L205.7) 348.5 (25.9) 344.4 (231.1L531.1)
$12 to 18 yr
(n ¼ 4)
AUC (mg/hr/ml) 24,308.7 (24.2) 24,155.5 (17,556.7L31,367.3) 110,279.1 (21.6) 103,362.9 (90,429.5L143,960.8)
Cmax (mg/ml) 172.4 (25.5) 173.6 (121.2L221) 456.4 (21.5) 437.8 (357.7L592.1)
Cmin (mg/ml) 120.9 (23.2) 118.3 (89.9L157) 227.0 (23.1) 215.2 (179.8L298.1)
Overall
(n ¼ 22)
AUC (mg/hr/ml) 42,607.2 (38.8) 39,700.1 (17,556.7L88,516.6) 136,163.2 (30.9) 141,741.4 (43,652.9L261,814.4)
Cmax (mg/ml) 301.5 (41.9) 276.6 (121.2L686.2) 528.6 (29.5) 515.4 (267.4L1094.4)
Cmin (mg/ml) 213.0 (37.2) 201.1 (89.9L396.2) 270.5 (37.8) 256.7 (50.2L531.1)
aAUC, area under the concentration time curve from day 0 to week 1 for the induction period and area under the concentration time curve under steady-state conditions;
Cmax, maximum concentration; Cmin, minimum concentration; CV(%), coefﬁcient of variation.
Table 5 | Treatment-emergent adverse events
Parameter
Intent-to-treat
population(N [ 22)
TEAEs (frequency $20%), n (%)
Fever 11 (50)
Cough 8 (36)
Abdominal pain 7 (32)
Diarrhea 7 (32)
Upper respiratory tract infection 7 (32)
Nasopharyngitis 6 (27)
Vomiting 6 (27)
Patients with TEAEs related to eculizumab, n (%)
Unrelated 11 (50)
Possiblya 8 (36)
Probablyb 1 (5)
Deﬁnite 0 (0)
Patients with any SAE, n (%) 13 (59)
Severity, n (%)
Mild 3 (14)
Moderate 7 (32)
Severe 3 (14)
SAEs occurring in 2 or more patients, n (%)
Fever 2 (9)
Gastroenteritis, viral 2 (9)
Hypertension 2 (9)
Upper respiratory tract infection 2 (9)
SAEs, serious adverse events; TEAEs, treatment-emergent adverse events.
aIncludes abdominal discomfort, agitation, alopecia, diaper dermatitis, diarrhea,
dyspepsia, ear infection, eye discharge, eczema, fungal infection, headache, injection
site rash, muscle spasms, nasopharyngitis, pain, rash, respiratory syncytial virus
infection, viral respiratory tract infection, viral upper respiratory tract infection (n ¼ 1
each).
bIncludes rash (n ¼ 1).
LA Greenbaum et al.: Eculizumab in pediatric patients with aHUS c l i n i ca l t r i a lBeneﬁts were observed in patients with or without identi-
ﬁed genetic abnormalities, including 1 patient with an
identiﬁed DGKE mutation. Health-related quality of life
signiﬁcantly improved after 26 weeks of therapy. The safety
proﬁle of eculizumab was consistent with previous studies
in aHUS,24 and no new safety concerns were noted. Overall,
ﬁndings are consistent with prospective clinical trials of
eculizumab in adults with aHUS and progressing TMA, in
adolescent and adult patients with a long disease history and
CKD,24,25 and in a retrospective study of pediatric patients
with aHUS.21
Signiﬁcantly greater recovery of renal function is achieved
when eculizumab is instituted as soon as possible after aHUS
presentation.24,40,41 In the current study, patients received
eculizumab approximately 2.5 weeks after diagnosis.
Although most had eGFR <30 ml/min per 1.73 m2 and half
were receiving dialysis at baseline, signiﬁcant eGFR increases
were observed as early as 1 week after initiation of therapy
and were maintained throughout the study. The observed
early and ongoing recovery of renal function, including CKD
improvement and discontinuation of dialysis, is compelling
considering that 29% of children with aHUS progress to end-
stage renal disease or die within 1 year when managed with
PE/PI.5 Overall, these ﬁndings are consistent with results from
a companion prospective study of eculizumab in adult
patients with aHUS.42
A post hoc analysis was performed to evaluate potential
baseline factors that may affect recovery of hematologic
and renal function as deﬁned by the primary end point of
complete TMA response. Although the small patient number
is limiting, patients who did not achieve complete TMA
response had a trend toward not having an identiﬁed com-
plement gene mutation and having worse renal function at
baseline. Additional studies are necessary to evaluate these
potential effects more rigorously.
In the current study, 55% of patients did not receive
previous PE/PI. Thus, this population differed from those inKidney International (2016) 89, 701–711pivotal clinical trials24 and exclusively adult patients,42 in
which 85% to 100% received PE/PI before starting eculizu-
mab. A recent report described an infant with aHUS who
received ﬁrst-line eculizumab, which was well tolerated and
led to hematologic and renal function improvement.43 Our
ﬁndings support recent recommendations to initiate eculi-
zumab after ruling out other potential causes of TMA and on
clinical diagnosis of aHUS in pediatric patients to achieve707
Table 6 | Schedule of eculizumab dose administration based
on patient weight
Weight cohort Induction Maintenance
c l i n i ca l t r i a l LA Greenbaum et al.: Eculizumab in pediatric patients with aHUSoptimal outcomes and to avoid potential complications
associated with PE/PI.13,44,45
This report includes the ﬁrst PK analyses of eculizumab in
a prospective clinical trial in children. Overall, the approved
pediatric dosing regimen resulted in eculizumab concentra-
tions of 50 to 700 mg/ml for all age cohorts, consistent with
those reported in the pivotal trials.24 One patient had evi-
dence of HAHAs, relatively low eculizumab concentrations,
decreased inhibition of hemolytic activity at 1 time point
during the maintenance phase, and remained on dialysis but
continued in the study without safety concerns. In pivotal
studies of eculizumab, neutralizing HAHAs were not detected
in patients with aHUS and were detected in about 1% of
patients with paroxysmal nocturnal hemoglobinuria without
correlations with clinical responses or AEs.21 In clinical
practice, HAHA testing can be reserved for rare scenarios in
which complement activity is suspected during ongoing
therapy.13
Recently, there was a report of liver toxicity associated with
eculizumab in a few patients with aHUS.46 In the current
study, elevated liver enzymes were noted in some patients
before and after receiving eculizumab. Overall, there was a
strong trend toward normalization of hepatic enzyme levels
after eculizumab initiation. Our ﬁndings suggest that the
increased alanine transaminase and aspartate aminotrans-
ferase levels seen in some patients after eculizumab initiation
may be related to pre-existing ongoing TMA that developed
before treatment initiation. In addition, these elevations were
transient and not associated with clinical AEs. Importantly,
no patient discontinued eculizumab because of elevated liver
enzyme levels or hepatic AEs.
Because this was an open-label study, interpretation of
these results may be limited by the lack of a control
group. Additionally, the deﬁnition of the primary end
point of complete TMA response required improvement
in serum creatinine levels. This deﬁnition excluded
patients who had hematologic normalization but irre-
versible kidney failure.
The availability of eculizumab has fundamentally
improved the outlook for patients with aHUS. This pro-
spective study conﬁrms that eculizumab inhibits
complement-mediated TMA and is well tolerated in children.
Prevention of hemolysis and improvement of renal function
during eculizumab therapy, without the need for PE/PI,
represents an important clinical beneﬁt. The ongoing exten-
sion treatment phase and a global aHUS registry study will
provide further insights regarding long-term use of eculizu-
mab in children with aHUS.$40 kg 900 mg weekly 4 1200 mg wk 5; 1200 mg q2 wk
30 to <40 kg 600 mg weekly 2 900 mg wk 3; 900 mg q2 wk
20 to <30 kg 600 mg weekly 2 600 mg wk 3; 600 mg q2 wk
10 to <20 kg 600 mg weekly 1 300 mg wk 2; 300 mg q2 wk
5 to <10 kg 300 mg weekly 1 300 mg wk 2; 300 mg q3 wk
q2 weeks, every 2 weeks.
Patients who required plasmapheresis or plasma infusion received a supplemental
dose of eculizumab 300 mg (if previous eculizumab dose was 300 mg) or 600 mg
(if previous dose was $600 mg).METHODS
Patients
From September 2010 through March 2012, patients aged 1 month
to 18 years with an aHUS diagnosis who weighed $5 kg were
enrolled at 17 clinical sites across North America, Europe, and
Australia. At screening, eligible patients had a platelet count less than
the lower limit of normal, LDH level $1.5 times the ULN,708hemoglobin less than or equal to the lower limit of normal, frag-
mented red blood cells with a negative Coombs test result, and
serum creatinine level $97th percentile for age. Patients with or
without an identiﬁed complement gene mutation, autoantibody, or
polymorphism (or all of these) were included; mutation testing (for
CFB, CFH, CFI, MCP, C3 mutations, CFHR1-CFHR3 poly-
morphisms, and CFH and CFI antibody titers) was performed at
regional laboratories if mutation status was unknown or negative
before study entry. Screening for DGKE mutations occurred in pa-
tients with onset at <1 year of age and evidence of proteinuria after
completion of the trial. Exclusion criteria included HUS of other
causes (ie, Shiga-like toxin-producing E coli) or severe a disintegrin
and metalloproteinase with a thrombospondin type 1 motif, member
13 (ADAMTS13) deﬁciency (<5%), PE/PI for >5 weeks before
enrollment, chronic dialysis for end-stage renal disease, and previous
use of eculizumab or hypersensitivity to its components.
All patients were vaccinated against Neisseria meningitidis,
Streptococcus pneumoniae, and Haemophilus inﬂuenzae 14 days or
more before initiation of treatment or received prophylactic antibi-
otics until 2 weeks after meningococcal vaccination to avoid delaying
therapy initiation. Patients #2 years old received antibiotic pro-
phylaxis throughout treatment, because at the time there was no
vaccine for individuals of this age group.
Study design
This was an open-label nonrandomized single-arm multicenter
phase II clinical trial of eculizumab in patients <18 years of age with
aHUS (ClinicalTrials.gov Identiﬁer: NCT01193348; registration
August 31, 2010), including a 7-day screening period, a 26-week
treatment period, an extension treatment period of up to 2 years,
and a 12-week safety follow-up period after eculizumab discontin-
uation. Patients who discontinued treatment were followed at
3-month intervals for 1 year to assess aHUS status and outcomes.
Eculizumab was administered at doses prespeciﬁed by body
weight (Table 6) based on previous experience with patients with
paroxysmal nocturnal hemoglobinuria and PK data to ensure
that $95% of patients had complete and sustained terminal com-
plement inhibition (including at times of increased complement
activity, e.g., infection or surgery) and to provide peak concentra-
tions (50–700 mg/ml) within the target range. Doses were adminis-
tered by intravenous infusion over approximately 1 to 4 hours at the
investigator’s discretion. If PE/PI was required, an additional eculi-
zumab dose was administered within 1 hour of treatment
completion.
The primary objective was to assess the efﬁcacy and safety of
eculizumab in patients with aHUS <18 years of age to inhibit
complement-mediated TMA, characterized by thrombocytopenia,
hemolysis, and renal impairment. The study protocol was approvedKidney International (2016) 89, 701–711
LA Greenbaum et al.: Eculizumab in pediatric patients with aHUS c l i n i ca l t r i a lby the institutional review board at each center or by an independent
ethics committee and was conducted in accordance with the Inter-
national Conference on Harmonisation Tripartite Guideline and the
Declaration of Helsinki. All patients or parents/guardians, or both,
provided written informed consent and assent if applicable.
Efﬁcacy end points
The primary end point was the proportion of patients who achieved
complete TMA response, deﬁned as hematologic normalization
(platelet count $ 150  109/L, LDH levels less than the ULN) and
improvement in renal function ($25% decrease in serum creatinine
level from baseline) on 2 consecutive measurements obtained $4
weeks apart. Time to complete TMA response was calculated from
the ﬁrst eculizumab dose to the day that the ﬁrst measurement was
obtained.
Secondary end points included TMA event-free status (no
decrease in platelet count >25% from baseline, no PE/PI, and no
new dialysis); the TMA intervention rate (the number of PE/PI and
new dialysis events per patient per day); hematologic normalization
(platelet count $ 150  109/L and LDH level less than the ULN);
hemoglobin increase $2 g/dL; $25% decrease in serum creatinine
levels; improvement in eGFR by $15 ml/min per 1.73 m2, and
improvement in CKD by $1 stage. eGFR was calculated using
the Schwartz formula—0.41  height (cm)/serum creatinine
(mg/dL)47—and deﬁned as 10 ml/min per 1.73 m2 while receiving
dialysis. Categorical end points were required to be sustained
for $2 consecutive measurements obtained $4 weeks apart. The
change in health-related quality of life from baseline was measured
using the pediatric Functional Assessment of Chronic Illness
Therapy—Fatigue questionnaire, designed for children 7 to 17 years
of age who could complete the questionnaire without help48 and
scored using standard algorithms.49 Mean changes from baseline in
platelet count, eGFR, and Functional Assessment of Chronic Illness
Therapy—Fatigue score were assessed at week 27 because of lack of
analysis points at week 26.
Baseline demographic and clinical characteristics of subgroups of
patients who did and those who did not meet criteria for the primary
end point were evaluated in a post hoc analysis.
Pharmacokinetic and pharmacodynamic assessments
Baseline and trough PK and pharmacodynamic blood samples for
determination of eculizumab concentrations and percent inhibition
of hemolysis50 were drawn after 24 hours and according to schedules
speciﬁc to each dosing weight cohort (Table 7). Samples were
collected before (trough) and 60 minutes after infusion (peak).
Serum concentrations were measured using a validated enzyme-
linked immunosorbent assay.51
Plasma eculizumab concentrations were ﬁtted to a
1-compartment model, used to support weight-based dosing of
eculizumab,52 to estimate PK parameters (AUC, Cmax, and Cmin).Table 7 | Pharmacokinetic and pharmacodynamic blood
sampling collection schedule by weight cohort
Weight cohort Peak Peak and trough Trough
$40 kg Wk 4 Wk 16 Wk 26
30 to <40 kg Wk 2 Wk 18 Wk 28
20 to <30 kg Wk 2 Wk 18 Wk 28
10 to <20 kg Wk 1 Wk 17 Wk 27
5 to <10 kg Wk 4 Wk 16 Wk 25
Kidney International (2016) 89, 701–711Safety assessments
Safety assessments included TEAEs. The presence of HAHAs was
assessed at weight cohort–speciﬁed time points (5 to <10 kg: weeks
0, 7, 13, and 15; 10 to <20 kg: weeks 0, 5, and 13; 20 to <30 kg and
30 to <40 kg: weeks 0, 6, and 14; $40 kg: weeks 0, 12, and 26) and
study termination. An electrochemiluminescence bridging assay
used eculizumab conjugated to biotin and to SULFO-TAG (Meso
Scale Diagnostics, LLC, Rockville, MD). Equimolar quantities of
the 2 conjugated eculizumab structures were added to the
serum-containing samples (2% [volume/volume]) and incubated
overnight. Samples were transferred to a blocked assay plate and
incubated at room temperature in the dark for 3 hours, followed by
washing and measurement of electrochemiluminescence with the
Sector Imager 2400 (Meso Scale Diagnostics, LLC; normalized
against a standard curve).
Statistical analysis
All analyses were performed in the intent-to-treat population,
deﬁned as all patients who received $1 eculizumab dose. Baseline
was deﬁned as the last value collected before the ﬁrst eculizumab
infusion. The baseline period for dialysis was deﬁned as 7 days
before until 14 days after the ﬁrst eculizumab dose. Complete
TMA response at week 26 was assessed using the Clopper-Pearson
method. For composite end points, patients were censored at the
last follow-up day if component data were missing. Patients
without valid values were treated as failures regarding end points.
The proportion of patients with eGFR improvement $15 ml/min
per 1.73 m2 was calculated similarly to the primary end point.
Platelet count, LDH level, hemoglobin value, serum creatinine
level, and eGFR values were summarized using descriptive statis-
tics. All statistical tests for efﬁcacy end points (including the
primary end point) were assessed at the 2-sided a ¼ 5% level
without adjusting for multiplicity. Descriptive statistics of PK
parameters were provided during the induction (i.e., after the ﬁrst
dose) and maintenance phase (i.e., at steady state) by age and
weight cohorts.
The planned number of patients to be enrolled was 20, based on
a postmarketing requirement to enroll $5 patients in each of
the following age cohorts: 1 month to <23 months, 24 months to
<5 years, and 5 to <12 years.DISCLOSURE
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